Originator Organization Vivace Therapeutics, Inc.Startup |
Active Organization Vivace Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC25H19F3N2O |
InChIKeyAAZUPSFRSHFTGV-INIZCTEOSA-N |
CAS Registry2417718-25-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | Vivace Therapeutics, Inc.Startup | 18 Sep 2021 |